摘要
目的对比研究小剂量托吡酯和普萘洛尔预防偏头痛发作的疗效及安全性。方法72例偏头痛患者随机分为两组,托吡酯组38例,给予托吡酯,第1周每日25 mg,第2周开始增加到每日50mg;普萘洛尔组34例,给予普萘洛尔,第1周每日40 mg,第2周开始增加到每日60mg,两组服药持续2个月。观察两组患者治疗前后的头痛发作频率、头痛程度和持续时间。结果托吡酯组治疗后头痛减少频率、头痛减轻程度与头痛减少时间均优于普萘洛尔组。结论小剂量托吡酯和普萘洛尔钠均能有效降低偏头痛患者发作频率、头痛程度和持续时间。但小剂量托吡酯较普萘洛尔的效果更好。
Objective To assess the efficacy and safety of low-dose topiramate in migraine prophylaxis and prop- ranolol. Methods 72 patients with migraine were randomly divided into two treatment groups-treated by topiramate and propranolol, respectively. The patients were assessed at 0, 4, and 8 weeks after treatment. Results The topiramate group showed a reduction of monthly migraine frequency from （ 6. 2±1.8 ） to （ 1.95±1.3 ） episodes per month and head- ache intensity from （7.9±1.4） score to （3.55±1.9） score, and headache duration from （15.25±6.3） to （6.85±4.1） hours （ all P〈0.01）. In the patients treated with propranolol, monthly headache frequency declined from （5.9± 1.6） to （ 2.3 5±1.4 ） per month, headache intensity lessened from （ 7.4 5±1.6 ） to （ 4.15±1.8 ） and headache duration decreased from （14.65±5.9） to （8.15±5.0） h （all P〈0.01）. Conclusions This study demonstrated that both low-dose topiramate and propranolol could significantly reduce migraine headache frequency, intensity, and duration. What＇s more, compared with propranolol, low-dose topiramate showed better results.
出处
《西部医学》
2009年第10期1705-1706,共2页
Medical Journal of West China
